24/7 Market News Snapshot 14 May, 2025 – Silo Pharma, Inc. Common Stock (NASDAQ:SILO)

May 14, 2025

DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (Nasdaq:SILO) are discussed in this article.
Silo Pharma, Inc. (Nasdaq:SILO), a biopharmaceutical company dedicated to developing innovative therapeutics for underserved medical conditions, recently announced a significant collaboration with Veloxity Labs, LLC. This partnership aims to conduct the necessary bioanalysis for the ongoing GLP-compliant toxicology and toxicokinetics study of Silo’s lead asset, SPC-15, which targets post-traumatic stress disorder (PTSD).

The announcement comes during a challenging time for Silo’s stock, which has experienced a notable decline of approximately 32.82%, trading down to $0.739 after opening at $0.99. The trading volume surged to 4.52 million shares, highlighting increased investor activity alongside the bearish momentum. This downturn may indicate heightened selling pressure, prompting potential investors to evaluate technical indicators that suggest oversold conditions, particularly around the $0.70 support level.

Despite the current market volatility, Silo’s CEO, Eric Weisblum, expressed optimism regarding the collaboration with Veloxity Labs, renowned for its rapid and high-quality data output. “The insights generated from this study are vital as we advance toward opening an Investigational New Drug (IND) application for SPC-15,” said Weisblum, underscoring the importance of this initiative.

The IND application is projected to commence in 2025, which will facilitate Silo Pharma’s progression towards initiating its first-in-human Phase 1 clinical trial upon receiving FDA approval. This strategic move is poised to address the urgent need for new treatments for PTSD, as well as complement Silo’s broader research efforts targeting a range of chronic conditions, including fibromyalgia, Alzheimer’s disease, and multiple sclerosis.

As Silo Pharma navigates through these market challenges, its focus on innovative biopharmaceutical solutions remains steadfast, aiming to enhance the quality of life for patients worldwide.

Related news for (SILO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.